Aktienanalyse zu Actuate Therapeutics Inc (ACTU)ACTUActuate Therapeutics Inc

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. It operates in the Healthcare sector.

Actuate Therapeutics Inc is not a strong buy at the moment due to its current price of $0.33, which is significantly below its 52-week high of $7.90 and reflects a year-to-date change of -94.45%. The RSI is at 28.68, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting no earnings growth is expected in the near term. The main risk is the negative earnings trend, with an EPS estimate of -0.18 for the next quarter.